Thalidomide - most significant drug in decades for multiple myeloma?

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1225, 2000-01, pp. : 11-12

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bortezomib: the current APEX of treatment for multiple myeloma?

Inpharma, Vol. 1, Iss. 1493, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Thalidomide as an Antiangiogenic Drug in the Treatment of Multiple Myeloma

Letters in Drug Design & Discovery, Vol. 1, Iss. 2, 2004-04 ,pp. : 135-136

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide in multiple myeloma

By García-Sanz Ramón

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 2, 2006-02 ,pp. : 195-213

Informa Healthcare

Access to resources Recommend Favorite

Thalidomide in Multiple Myeloma

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 6, 2006-12 ,pp. : 431-440

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide in multiple myeloma – clinical trials and aspects of drug metabolism and toxicity

By Breitkreutz Iris Anderson Kenneth C

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 7, 2008-07 ,pp. : 973-985

Informa Healthcare

Access to resources Recommend Favorite